GoKawiilEncora Therapeutics wins FDA clearance for wristband tremor device born from MIT class project
A wearable device that vibrates the wrist to reduce tremor symptoms, originally built by MIT students in a 2017 product engineering course, has received FDA clearance for treating essential tremor in adults. The student team formally launched as Encora Therapeutics in 2020 and ran clinical trials, with one study finding 78 percent of participants reported benefits after 90 days of home use. Co-founder Daniel Carballo described the near decade-long process from prototype to clearance as difficult but rewarding.
GoKawiil's interpretation of the reporting above, not reported fact.
The case illustrates how a classroom prototype can, over many years and iterations, mature into a regulated medical device, highlighting the gap between a compelling demo and a commercially viable, FDA-approved product. Essential tremor affects many adults, so a noninvasive wearable alternative to medication or surgery could expand treatment options, though real-world efficacy and adoption will depend on further use beyond trial settings. The 78 percent figure comes from the company's own reported trial data.
- A 2017 MIT class project evolved into Encora Therapeutics, founded in 2020.
- The FDA cleared the wristband device in February for adults with essential tremor.
- A company-reported trial found 78 percent of patients noted benefits after 90 days of home use.
Source: news.mit.edu — Zach Winn, 2026-10-12
Published there as: “MIT class project turns into an FDA-cleared treatment for tremors”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.